# NCT03600701 (NCT03600701)

> Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: atezolizumab plus cobimetinib
- Indication: PD-1/PD-L1 inhibitor-resistant or refractory non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03600701
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
- Interventions: Atezolizumab; Biopsy Procedure; Biospecimen Collection; Cobimetinib; Computed Tomography; Magnetic Resonance Imaging
- Enrollment: 53
- Primary outcome: Number of Participants With a Durable Response

## Indexed commentary on NCT03600701 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03600701